For UK healthcare professionals.
The information on this site is intended for UK healthcare professionals only. If you are a healthcare professional looking to find out more about EYLEA® (aflibercept), please It is recommended that you close your browser after you have finished viewing the site.
For members of the public
If you are not a healthcare professional and you want to learn about EYLEA® (aflibercept) pleasePP-EYL-GB-0749
Date of preparation: May 2021
Prescribing information and adverse event reporting can be found at the bottom of this page
This website is intended for UK healthcare professionals only
Prescribing information and adverse event reporting can be found at the bottom of this page. This website is intended for UK healthcare professionals only.
For UK healthcare professionals
The information on this site is intended for UK healthcare professionals only. If you are a healthcare professional, please It is recommended that you close your browser after you have finished viewing the site. This website contains promotional material.
For members of the public
If you are not a healthcare professional, pleasePP-EYL-GB-1697
Date of preparation: May 2023
We recommend that you use the latest version of your web browser for the best experience on eylea.co.uk.
EYLEA® (aflibercept) 8 mg:
Great Britain Prescribing Information (PI)
Northern Ireland Prescribing Information (PI)
Great Britain Summary of Product Characteristics (SmPC)
Great Britain Patient Information Leaflet (PIL)
EYLEA® (aflibercept) 2 mg:
Great Britain Prescribing Information (PI)
Northern Ireland Prescribing Information (PI)
Copyright © 2024, Bayer plc
This website has been developed and fully funded by Bayer plc and contains promotional content. Intended for UK healthcare professionals only.
PP-EYL-GB-2157 | February 2024
